Table 1.
Patient demographics and tumor characteristics by age.
| N | <40.0 N = 336 |
40.0–50.0 N = 403 |
50.0–60.0 N = 322 |
60.0–70.0 N = 195 |
≥70.0 N = 63 |
Test statistic | |
|---|---|---|---|---|---|---|---|
| Payer | 1319 | p < 0.001a | |||||
| Private | 26.8% (90) | 38.2% (154) | 40.7% (131) | 21.5% (42) | 7.9% (5) | ||
| Medicare | 1.2% (4) | 0.7% (3) | 1.6% (5) | 20.0% (39) | 54.0% (34) | ||
| Medicare + private | 0.6% (2) | 0.5% (2) | 0.6% (2) | 6.2% (12) | 11.1% (7) | ||
| Medicaid | 28.3% (95) | 19.9% (80) | 17.4% (56) | 10.3% (20) | 9.5% (6) | ||
| Medicaid + Medicare | 0.9% (3) | 0.0% (0) | 1.2% (4) | 2.1% (4) | 1.6% (1) | ||
| Military or veterans | 3.3% (11) | 0.7% (3) | 3.1% (10) | 2.1% (4) | 0.0% (0) | ||
| Other government | 5.4% (18) | 5.0% (20) | 5.3% (17) | 5.1% (10) | 3.2% (2) | ||
| Self/uninsured | 23.2% (78) | 25.8% (104) | 18.6% (60) | 23.1% (45) | 3.2% (2) | ||
| Unknown | 10.4% (35) | 9.2% (37) | 11.5% (37) | 9.7% (19) | 9.5% (6) | ||
| Race/ethnicity | 1319 | p = 0.014a | |||||
| White | 56.5% (190) | 62.0% (250) | 63.0% (203) | 62.6% (122) | 55.6% (35) | ||
| Black | 24.7% (83) | 20.3% (82) | 19.6% (63) | 21.5% (42) | 19.0% (12) | ||
| Hispanic | 16.1% (54) | 11.9% (48) | 9.3% (30) | 10.8% (21) | 17.5% (11) | ||
| Asian | 1.2% (4) | 3.2% (13) | 6.2% (20) | 4.6% (9) | 7.9% (5) | ||
| Other | 1.5% (5) | 2.5% (10) | 1.9% (6) | 0.5% (1) | 0.0% (0) | ||
| Performance status | 1319 | p = 0.006a | |||||
| Normal, asymptomatic | 65.5% (220) | 71.0% (286) | 64.6% (208) | 65.1% (127) | 47.6% (30) | ||
| Symptomatic, ambulatory | 31.5% (106) | 25.1% (101) | 32.3% (104) | 30.3% (59) | 41.3% (26) | ||
| Symptomatic, in bed | 3.0% (10) | 4.0% (16) | 3.1% (10) | 4.6% (9) | 11.1% (7) | ||
| Histology | 1319 | p = 0.91a | |||||
| Squamous | 85.1% (286) | 88.1% (355) | 88.5% (285) | 88.7% (173) | 85.7% (54) | ||
| Adenosquamous | 6.5% (22) | 5.2% (21) | 5.0% (16) | 5.6% (11) | 4.8% (3) | ||
| Adenocarc., other | 8.3% (28) | 6.7% (27) | 6.5% (21) | 5.6% (11) | 9.5% (6) | ||
| Tumor size cm | 1308 | 5.0 6.0 7.5 | 5.0 6.0 7.0 | 5.0 6.0 7.0 | 4.7 6.0 7.0 | 4.0 5.2 6.0 | p = 0.003b |
| FIGO stage | 1319 | p = 0.144a | |||||
| IB | 6.5% (22) | 5.2% (21) | 4.7% (15) | 3.1% (6) | 1.6% (1) | ||
| IIA | 1.2% (4) | 1.2% (5) | 3.1% (10) | 1.0% (2) | 3.2% (2) | ||
| IIB | 61.9% (208) | 52.9% (213) | 52.8% (170) | 51.3% (100) | 50.8% (32) | ||
| IIIA | 1.2% (4) | 0.7% (3) | 1.2% (4) | 2.1% (4) | 1.6% (1) | ||
| IIIB | 27.1% (91) | 36.5% (147) | 34.2% (110) | 37.9% (74) | 39.7% (25) | ||
| IVA | 2.1% (7) | 3.5% (14) | 4.0% (13) | 4.6% (9) | 3.2% (2) | ||
| Tumor grade (differentiation) | 1319 | p = 0.769a | |||||
| Good | 8.0% (27) | 6.9% (28) | 6.2% (20) | 5.6% (11) | 7.9% (5) | ||
| Moderate | 58.3% (196) | 62.8% (253) | 59.6% (192) | 62.6% (122) | 65.1% (41) | ||
| Poor | 31.0% (104) | 28.8% (116) | 33.2% (107) | 30.3% (59) | 27.0% (17) | ||
| Not graded | 2.7% (9) | 1.5% (6) | 0.9% (3) | 1.5% (3) | 0.0% (0) |
Numbers after percents are frequencies.
a
Test used: Pearson test
b
Test used: Kruskal-Wallis test.